跳转到主要内容
搜索

出版物

注册

Featured publication

尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型
尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型

尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型

This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a PARP inhibitor used in advanced ovarian cancer, using data…

Latest publications

Popular publications

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome
Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics
Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

Model-Based Patient Selection and Dosing Strategies for HRAS and PIK3CA Dysregulated HNSCC: A QSP Model for Alpelisib and Tipifarnib Combination
Model-Based Patient Selection and Dosing Strategies for HRAS and PIK3CA Dysregulated HNSCC: A QSP Model for Alpelisib and Tipifarnib Combination

Model-Based Patient Selection and Dosing Strategies for HRAS and PIK3CA Dysregulated HNSCC: A QSP Model for Alpelisib and Tipifarnib Combination

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis
Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis

Collection
Simcyp Publications and Independent Applications

We are proud to share our publications by the Simcyp R&D Team (1997 – Present) and independent applications of Simcyp by industry, academia, and regulatory organizations (2007 – Present).

了解更多信息

All publications

尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型

Publication Certara Services Clinical Pharmacology Drug Development Model Informed Drug Development Modeling and Simulation Modeling and Simulation - PK/PD Oncology/Hematology Therapeutic Specialties

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

Publication Cardiovascular Certara Services Clinical Pharmacology Clinical Trials Drug Development Drug Safety Model Informed Drug Development Modeling and Simulation Modeling and Simulation – PK/PD Therapeutic Specialties

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Publication Certara Services Clinical Pharmacology Clinical Trials Drug Development Drug Safety Drug-Drug Interactions (DDI) Model Informed Drug Development Modeling and Simulation Modeling and Simulation – PK/PD Therapeutic Specialties

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Publication Certara Services Clinical Pharmacology Clinical Trials Drug Development Drug Safety Model Informed Drug Development Modeling and Simulation Modeling and Simulation – PK/PD Therapeutic Specialties

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome

Publication Certara Products - Certara IQ Modeling and Simulation Modeling and Simulation - QSP

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Publication Certara Services Clinical Pharmacology Clinical Trials Drug Development Drug Safety Model Informed Drug Development Modeling and Simulation - PK/PD Therapeutic Specialties

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

Publication Clinical Pharmacology Drug Development Drug Safety Model Informed Drug Development Modeling and Simulation Modeling and Simulation - PK/PD Therapeutic Specialties

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

Publication Biologics Cardiovascular Certara Services Clinical Pharmacology Clinical Trials Drug Development Model Informed Drug Development Modeling and Simulation Modeling and Simulation - PBPK

Model-Based Patient Selection and Dosing Strategies for HRAS and PIK3CA Dysregulated HNSCC: A QSP Model for Alpelisib and Tipifarnib Combination

Publication Modeling and Simulation Modeling and Simulation - QSP Oncology/Hematology
Be the first to get the latest

Transforming drug development is not just our goal—it’s our obsession. 如果这也是您的想法，那么请第一时间了解新见解，与我们一起推动科学发展。


沪ICP备2022021526号
Powered by Translations.com GlobalLink Web Software